Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/24/2026 | $8.00 | Outperform | Oppenheimer |
| 6/2/2025 | $7.00 | Outperform | Oppenheimer |
| 12/17/2024 | $17.00 | Overweight | Cantor Fitzgerald |
| 5/10/2024 | $8.00 | Outperform | Leerink Partners |
| 4/11/2024 | $10.00 | Overweight | Piper Sandler |
| 3/28/2024 | $7.00 | Outperform | Raymond James |
Reaffirms guidance to resubmit Anaphylm™ (dibutepinephrine) sublingual film NDA in Q3 2026Affirms existing clinical data is sufficient for submitting regulatory applications in Canada, European Union, and the United KingdomCompleted AQST-108 phase 1 study in subjects with androgenic alopecia with no safety issues observedEntered into a $150 million debt facility with Oaktree Capital Management, L.P.Company to host investor call on May 14, 2026, at 8:00am ET WARREN, N.J., May 13, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovativ
WARREN, N.J., May 12, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the refinancing of its existing debt facility with a new $150 million debt facility with funds managed by Oaktree Capital Management, L.P. ("Oaktree"). This transaction provides additional flexibility to fund the launch of Anaphylm™, if approved by the FDA. At closing, Oaktree provided $55.0 million, which was primarily used to repay the Company's existing loan in the aggregate principal amount of $45 mi
WARREN, N.J., May 06, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that it will report results for the first quarter ended March 31, 2026 and provide an update on recent developments in its business after market close on Wednesday, May 13, 2026. Management will host a conference call for investors at 8:00 a.m. ET on Thursday, May14, 2026. To participate, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webcast of t
Submission status for AQUESTIVE THERAPEUTICS INC's drug LIBERVANT (ORIG-1) with active ingredient DIAZEPAM has changed to 'Approval' on 04/26/2024. Application Category: NDA, Application Number: 218623, Application Classification: Type 9 - New Indication Submitted as Distinct NDA, Consolidated with Original NDA after Approval
10-Q - Aquestive Therapeutics, Inc. (0001398733) (Filer)
8-K - Aquestive Therapeutics, Inc. (0001398733) (Filer)
DEFA14A - Aquestive Therapeutics, Inc. (0001398733) (Filer)
4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)
Oppenheimer resumed coverage of Aquestive Therapeutics with a rating of Outperform and set a new price target of $8.00
Oppenheimer resumed coverage of Aquestive Therapeutics with a rating of Outperform and set a new price target of $7.00
Cantor Fitzgerald initiated coverage of Aquestive Therapeutics with a rating of Overweight and set a new price target of $17.00
Reaffirms guidance to resubmit Anaphylm™ (dibutepinephrine) sublingual film NDA in Q3 2026Affirms existing clinical data is sufficient for submitting regulatory applications in Canada, European Union, and the United KingdomCompleted AQST-108 phase 1 study in subjects with androgenic alopecia with no safety issues observedEntered into a $150 million debt facility with Oaktree Capital Management, L.P.Company to host investor call on May 14, 2026, at 8:00am ET WARREN, N.J., May 13, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovativ
WARREN, N.J., May 06, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that it will report results for the first quarter ended March 31, 2026 and provide an update on recent developments in its business after market close on Wednesday, May 13, 2026. Management will host a conference call for investors at 8:00 a.m. ET on Thursday, May14, 2026. To participate, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webcast of t
Reaffirms guidance to resubmit Anaphylm™ (dibutepinephrine) sublingual film NDA in Q3 2026; Type A meeting with FDA expected to occur within 30 daysOn track to submit regulatory applications for Anaphylm in Canada and the EU in 2026Extends revenue sharing agreement with RTW to June 30, 2027Excluding one-time items, meets 2025 guidance for revenue and non-GAAP adjusted EBITDA lossGuides to end FY2026 with cash and cash equivalents of $70 millionCompany to host investment community conference call on March 5, 2026 WARREN, N.J., March 04, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring m
SC 13G/A - Aquestive Therapeutics, Inc. (0001398733) (Subject)
SC 13G - Aquestive Therapeutics, Inc. (0001398733) (Subject)
SC 13G - Aquestive Therapeutics, Inc. (0001398733) (Subject)
Thomas A. Zalewski, a Partner at Day Pitney LLP, appointed Chief Legal Officer and Chief Compliance Officer effective April 2, 2026Lori J. Braender to remain in a non-executive role as Corporate Secretary after nearly eight years as Chief Legal Officer, Chief Compliance Officer and Corporate Secretary WARREN, N.J., March 20, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the appointment of Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer, effective Apr
Board-certified allergist and leading food allergy and anaphylaxis researcher joins Aquestive to support Anaphylm™ (dibutepinephrine) sublingual film NDA resubmission and pipeline WARREN, N.J., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the appointment of Matthew Greenhawt, MD, MBA, MSc, as Chief Medical Officer, strengthening its leadership team as the Company prepares to resubmit its Anaphylm™ New Drug Application (NDA) to the United Stated Food and Drug Admi
WARREN, N.J., June 18, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced its expected addition to the broad-market Russell 3000® and Russell 2000® Indexes at the conclusion of the 2024 Russell U.S. indexes annual reconstitution, effective at the open of U.S. equity markets on Monday, July 1, according to a preliminary list of additions posted Friday, May 24, 2024. "We are honored that Aquestive is joining the Russell 3000 Index, which represents the 3,000 largest U.S. public